At 7.5% CAGR, the Asia Pacific Enteral and Parenteral Medical Nutrition Market is projected to be worth US$ 3,352.69 million by 2028, says Business Market Insights

According to Business Market Insights research, the Asia Pacific enteral and parenteral medical nutrition market was valued at US$ 2,339.32 million in 2023 and is expected to reach US$ 3,352.69 million by 2028, registering a CAGR of 7.5% from 2023 to 2028. Rise in prevalence of gastrointestinal diseases and increasing cases of malnutrition and premature births are the critical factors attributed to the Asia Pacific enteral and parenteral medical nutrition market expansion.        

There is a surge in the demand for products that help consumers proactively manage their health, especially those focused on specific needs in terms of energy levels, immunity, and disease treatment. Nutritional requirements differ based on the type of illness. Functionality and specific formulations of the enteral and parenteral products do not interfere with the existing treatment provided to patients and help deliver a more precise and enhanced treatment as per the requirement. The macro and micronutrient formulations of enteral and parenteral nutrition and its applications vary based on various diseases, such as cancer and gastrointestinal diseases. Isocaloric enteral nutrition formulation (1 kcal/ml) is generally prescribed to achieve estimated or measured caloric goals, while energy-dense formulae (>1 kcal/ml) are prescribed to increase calorie delivery in patients with gastrointestinal dysfunction. Moreover, pharmaceutical companies provide enteral and parenteral nutrition with individualized (patient-specific) constituents. Standardized parenteral nutrition products contain fixed constituents and are designed to meet the average patient’s nutritional requirements considering different requirements in different age groups. These nutrition products can be sourced as institution-specific standardized formulations or patient-specific formulations. For example, Impact (offered by Nestle) is a clinically proven nutritional solution for managing patients undergoing major elective surgeries to reduce postoperative complications and hospital stay duration and improve clinical outcomes. Peptamen Formula (Nestle) is the only peptide-based formula with enzymatically hydrolyzed 100% whey protein that helps overcome tube-feeding intolerance. Such tube-feeding formulas are specialized enteral nutrition products designed to support absorption and overcome tolerance mechanisms in individuals with gastrointestinal disorders. Calogen by Nutricia is a high-energy, long-chain triglyceride fat emulsion oral nutritional supplement used to manage conditions requiring a high energy intake. Various organizations are making efforts to spread awareness of the use of specific nutritional formulations.

Further, a surge in the number of people turning to plant-based food triggers the demand for plant-based nutrition products worldwide. People are more likely to show intolerance to artificial/synthetically sourced ingredients used in higher numbers, which may lead to adverse reactions. Thus, the fewer ingredients, the better the final product. The Innova Consumer Survey 2020 showed that health, diet variety, sustainability, and taste are among the top reasons why people consider plant-based alternatives. According to Abbott, consumers and patients relying on tube feeding are no exception to this trend.  For instance, in August 2021, Kate Farms launched the first closed feeding system delivering plant-based formulas in a ready-to-hang 1-liter bag. Kate Farms Standard 1.4 plain and Peptide 1.5 plain formulations are plant-based, organic, calorically dense products, which are used as a sole source of supplemental nutrition in tube feeding. In September 2021, Abbott introduced a portfolio of plant-based proteins and organic food ingredients for children and adults. Similarly, olive oil-based parenteral nutrition products are also gaining popularity. Therefore, functional, and patient-centric formulations and plant-based nutrition products are the prime emerging trends in the enteral and parenteral medical nutrition market.

On the contrary, mechanical, gastrointestinal, and metabolic complications associated with enteral and parenteral feeding systems, and limitations related to catheter placement hampers the Asia Pacific Enteral and Parenteral Medical Nutrition Market.  

Based on indication, the Asia Pacific enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held 30.4% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 710.48 million. It is projected to garner US$ 1,028.57 million by 2028 to expand at 7.7% CAGR during 2023–2028.

Based on nutrition type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held 79.0% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 1,848.53 million. It is projected to garner US$ 2,631.51 million by 2028 to expand at 7.3% CAGR during 2023–2028.

Based on form, the Asia Pacific enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held 53.1% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 1,242.39 million. It is projected to garner US$ 1,768.59 million by 2028 to expand at 7.3% CAGR during 2023–2028.

Based on product type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held 57.7% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 1,350.91 million. It is projected to garner US$ 1,952.70 million by 2028 to expand at 7.6% CAGR during 2023–2028.

Based on route of administration, the Asia Pacific enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held 43.9% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 1,026.10 million. It is projected to garner US$ 1,461.14 million by 2028 to expand at 7.3% CAGR during 2023–2028.

Based on age group, the Asia Pacific enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held 39.4% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 922.58 million. It is projected to garner US$ 1,326.92 million by 2028 to expand at 7.5% CAGR during 2023–2028.

Based on distribution channel, the Asia Pacific enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held 41.0% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 960.17 million. It is projected to garner US$ 1,360.33 million by 2028 to expand at 7.2% CAGR during 2023–2028.

Based on country, the Asia Pacific enteral and parenteral medical nutrition market has been categorized into China, Japan, India, Australia, South Korea, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. Our regional analysis states that China captured 24.6% share of Asia Pacific Enteral and Parenteral Medical Nutrition Market in 2023. It was assessed at US$ 574.68 million in 2023 and is likely to hit US$ 842.84 million by 2028, exhibiting a CAGR of 8.0% during the forecast period.      

Key players operating in the Asia Pacific enteral and parenteral medical nutrition market are Abbott Laboratories; B. Braun SE; Baxter International Inc; Fresenius Kabi AG; Nestle SA; and Nutricia International BV, among others.  

• November 2021, Abbott Launched Similac 360 Total Care to Support the Immune System, Digestive Health and Brain Development. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby’s health and development, including the developing immune system, digestive system and brain.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com